D. Shames
Papers
1
Total Citations
35
H-Index
1
About
D. Shames is a leading translational researcher in oncology, specializing in liquid biopsy biomarkers and immunotherapy response in non-small cell lung cancer (NSCLC). Their most-cited work, a 2021 study on dynamic circulating tumour DNA (ctDNA) response to neoadjuvant atezolizumab and surgery, has garnered 35 citations and represents a pivotal contribution to precision oncology. Shames demonstrated that real-time ctDNA monitoring can predict treatment outcomes and guide surgical decisions, offering a non-invasive tool to assess immunotherapy efficacy. This research bridges molecular biology and clinical practice, providing a framework for personalized neoadjuvant strategies. By integrating ctDNA dynamics with pathological response, Shames has advanced the understanding of how liquid biopsies can optimize patient stratification and early intervention in NSCLC. Their work is widely cited for its methodological rigor and translational relevance, influencing ongoing trials in immuno-oncology. Shames continues to shape the field through collaborative efforts that refine biomarker-driven approaches, making their research essential for students and clinicians exploring the intersection of genomics, immunotherapy, and surgical oncology.
Research Focus
Key Achievements
Top Papers
- 1